NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

240.68B

Vuru Grade

68.09/100

Current Price

$100.34
+0.78 (+0.78%)

Growth Price

$64.04
Overvalued by 36.18%

Stability Price

$21.84
Overvalued by 78.23%

Company Metrics

  • 24.3 P/E
  • 4.45 P/S
  • 3.37 P/B
  • 4.13 EPS
  • 12.42% Cash ROIC
  • 0.51 Cash Ratio
  • 2.82 / 2.8% Dividend
  • 2.06M Avg. Vol.
  • 2.40B Shares
  • 240.68B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bidness ETC - Mar 24, 2015
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
New Blockbuster Drugs Expected From Sanofi SA (ADR) (NYSE:SNY), Bristol ... - NYSE Post
Amgen, Inc. Petition Against Novartis AG (ADR) Denied By Court- Biosimilar ...
Bidness ETC - Mar 20, 2015
A US judge has struck down Amgen Inc.'s (NYSE:AMGN) petition to prevent Novartis AG ADR (NYSE:NVS) launching a biosimilar version of its blockbuster neutropenia treatment drug, Neupogen, in the US.
Novartis AG (ADR) Cosentyx More Effective Than Johnson & Johnson Stelara
Bidness ETC - Mar 14, 2015
Novartis AG (ADR) (NYSE:NVS) announced yesterday that results from a late-stage clinical trial demonstrated that Cosentyx, its new treatment for psoriasis, outperformed Johnson & Johnson's (NYSE:JNJ) blockbuster drug Stelara.
Novartis AG (ADR) Slapped With $110 Million Gender Discrimination Lawsuit
Bidness ETC - Mar 18, 2015
Novartis AG (ADR) (NYSE:NVS) will have to defend itself in US courts over claims that the Swiss-based drug giant has routinely denied female employees at its US division equal pay and career growth opportunities.
Novartis Involved in Another Gender Discrimination Lawsuit - Financialbuzz.com
Gender Discrimination Lawsuit Filed Against Novartis AG (ADR)(NYSE:NVS)
WallStreet.org - Mar 19, 2015
It was filed by two individuals who had formerly been the employees of Novartis AG (ADR) (NYSE:NVS). They claimed that the company has acquired a unit in the year 2010 worth $51 billion, namely Alcon laboratories Ltd.
Arrowhead Research Corp To Acquire Novartis AG (ADR) RNAi Assets
Bidness ETC - Mar 6, 2015
Arrowhead Research Corp (NASDAQ:ARWR), which develops targeted RNAi therapeutics, announced Thursday that it will acquire Novartis AG's (ADR) (NYSE:NVS) RNAi research and development portfolio and other assets in efforts to strengthen its work in ...
Small Cap Stocks Under Consideration - Arrowhead Research (ARWR),Neustar ... - Investor Wired
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
Bidness ETC - Feb 26, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (ADR) Zarxio Becomes First Biosimilar Approved For Sale In US
Bidness ETC - Mar 9, 2015
Novartis AG (ADR) (NYSE:NVS) on Friday won the US Food and Drug Administration's (FDA) approval for its biosimilar drug Zarxio, a cheaper imitation version of Amgen, Inc.'s (NASDAQ:AMGN) Neupogen, making Zarxio the first ever biosimilar to be ...
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...
Bidness ETC - Mar 2, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ... - Stocks.org
GlaxoSmithKline plc (ADR) (NYSE:GSK) Update: GlaxoSmithKline sees Novartis ... - Ashburn Daily
Novartis AG (ADR) Ordered To Halt Some Japanese Operations
Bidness ETC - Feb 27, 2015
The Japanese Health Ministry has ordered Novartis AG ADR (NYSE: NVS) to halt most of its operations in Japan for 15 days in March, claiming that the company had failed to report side-effects caused by its products within a pre-specified time.